JP2024516098A5 - - Google Patents
Info
- Publication number
- JP2024516098A5 JP2024516098A5 JP2023561864A JP2023561864A JP2024516098A5 JP 2024516098 A5 JP2024516098 A5 JP 2024516098A5 JP 2023561864 A JP2023561864 A JP 2023561864A JP 2023561864 A JP2023561864 A JP 2023561864A JP 2024516098 A5 JP2024516098 A5 JP 2024516098A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence represented
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110405638.3 | 2021-04-15 | ||
| CN202110405638 | 2021-04-15 | ||
| PCT/CN2022/086842 WO2022218380A1 (zh) | 2021-04-15 | 2022-04-14 | 靶向bcma的多特异性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516098A JP2024516098A (ja) | 2024-04-12 |
| JP2024516098A5 true JP2024516098A5 (https=) | 2025-03-18 |
Family
ID=83640152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561864A Pending JP2024516098A (ja) | 2021-04-15 | 2022-04-14 | Ｂｃｍａを標的とする多重特異性抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240182592A1 (https=) |
| EP (1) | EP4324853A4 (https=) |
| JP (1) | JP2024516098A (https=) |
| KR (1) | KR20230170721A (https=) |
| CN (1) | CN117062840A (https=) |
| AU (1) | AU2022256638A1 (https=) |
| BR (1) | BR112023020341A2 (https=) |
| CA (1) | CA3214012A1 (https=) |
| IL (1) | IL307308A (https=) |
| MX (1) | MX2023011923A (https=) |
| TW (1) | TW202304963A (https=) |
| WO (1) | WO2022218380A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12612635B2 (en) | 2020-08-20 | 2026-04-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BCMA-binding single variable structural domain and antigen-binding molecule |
| JP7821161B2 (ja) * | 2020-08-20 | 2026-02-26 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 |
| KR20260005269A (ko) * | 2023-04-24 | 2026-01-09 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | c-Met를 표적으로 하는 다중 특이성 항체 |
| CN119119246B (zh) * | 2024-06-26 | 2025-10-10 | 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) | 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018028647A1 (en) | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| KR20250007003A (ko) * | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| WO2019195535A1 (en) | 2018-04-05 | 2019-10-10 | Novartis Ag | Trispecific binding molecules against cancers and uses thereof |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| JP7821161B2 (ja) * | 2020-08-20 | 2026-02-26 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 |
| CN112794916B (zh) * | 2021-04-08 | 2021-08-10 | 正大天晴药业集团南京顺欣制药有限公司 | 三特异性抗原结合构建体及构建方法和应用 |
-
2022
- 2022-04-14 WO PCT/CN2022/086842 patent/WO2022218380A1/zh not_active Ceased
- 2022-04-14 TW TW111114188A patent/TW202304963A/zh unknown
- 2022-04-14 EP EP22787602.6A patent/EP4324853A4/en active Pending
- 2022-04-14 IL IL307308A patent/IL307308A/en unknown
- 2022-04-14 MX MX2023011923A patent/MX2023011923A/es unknown
- 2022-04-14 CN CN202280022841.5A patent/CN117062840A/zh active Pending
- 2022-04-14 AU AU2022256638A patent/AU2022256638A1/en active Pending
- 2022-04-14 KR KR1020237038699A patent/KR20230170721A/ko active Pending
- 2022-04-14 BR BR112023020341A patent/BR112023020341A2/pt unknown
- 2022-04-14 JP JP2023561864A patent/JP2024516098A/ja active Pending
- 2022-04-14 CA CA3214012A patent/CA3214012A1/en active Pending
- 2022-04-14 US US18/285,511 patent/US20240182592A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2024516098A5 (https=) | ||
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| EP3561057A1 (en) | Anti-cd3 antibody, and molecule containing said antibody | |
| JP2021524478A5 (https=) | ||
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| CN106632674A (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
| JP2022533538A5 (https=) | ||
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| CA2875451A1 (en) | Antibody against transporter and use thereof | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2024540148A5 (https=) | ||
| CA3022961A1 (en) | Anti-kv1.3 antibodies, and methods of production and use thereof | |
| JP2023506834A5 (https=) | ||
| CN112236456B (zh) | 新型双特异性pd-1/lag-3抗体分子 | |
| JP2024516621A5 (https=) | ||
| CN113549152B (zh) | 一种抗basigin人源化抗体及其应用 | |
| IL295993A (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| US12606628B2 (en) | Antibodies targeting integrin beta-2 | |
| CN120040594B (zh) | 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用 | |
| WO2025146161A1 (en) | Antibody, antigen-binding fragment and medical use thereof | |
| WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| WO2025190376A1 (zh) | 抗cd161抗体及其用途 |